The cannabis industry is on the cusp of a potentially major shakeup, as the U.S. Drug Enforcement Administration (DEA) considers a recommendation to reschedule marijuana from a Schedule I drug to the less restrictive Schedule III. This would be a regulatory boon for companies in the business of cannabis, which is already projected for substantial growth; Grand View Research is forecasting a CAGR of 25.5% for the global legal cannabis market through 2030.
Against this backdrop, here's a look at one small-cap cannabis stock that's priced at less than $3 per share right now, and potentially primed for major upside based on analysts' forecasts.
